Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

NCT05798793 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

309

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab plus TP
DRUG: TP

Sponsor

Hospital of Stomatology, Wuhan University

Collaborators

[object Object]